This is a copy of the slides presented at the meeting but not formally written up for the volume.

Several programs in the NCI nanotech seek to develop unique platforms for targeted drug delivery. These platforms involve the use of nanometer-sized macromolecules and nanoparticles. Requirements should include a diameter small enough that the drug and carrier will escape the blood stream through vascular pores and then specifically target cells within tumors or selected organs. Importantly, these platforms should also internalize within a cell and localize to intracellular structures. Achieving proof of concept with these technologies would then require additional funding from venture capital or private corporate investment to support human clinical trials. Given the activity of nanoparticles for drug, this technology has the potential to revolutionize therapeutics and provide unique solutions for all aspects of cancer care. The potential risks, benefits and technical requirements for these platforms will be reviewed. Different technologies will be compared and contrasted for the ability to meet the need of cancer therapeutics.